Our people in the organization are a source of pride. We have put together an outstanding team of individuals that are focused on achieving our goals and our mission ‘to improve lives together’.
What sets us apart
Our lead medicine is approved for the treatment of iron deficiency with or without anemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid 2030s.
In Europe the medicine is marketed as Feraccru® with commercialization led by Norgine BV.
We also have partners in China, Canada and Republic of Korea. Please see our Global Partners page for more information.
Shield’s proprietary lead product, ACCRUFeR®/Feraccru®, has been approved for use in the US, the EU, the UK, Australia and Switzerland. The product has patent coverage until 2035. The Company recently launched ACCRUFeR® in the US. Feraccru® is being commercialised in the UK and EU by Norgine BV, which also has the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, with KYE Pharmaceuticals Inc. in Canada, and with AOP Orphan Pharmaceuticals AG in Egypt, Jordan, Russia, Saudi Arabia, Syria, Turkey, Ukraine and United Arab Emirates.
The skilled Senior Executive Team and Board of Directors provide strong leadership for the Company’s future growth.
The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. Ferric maltol (marketed as ACCRUFeR®/Feraccru®) for the treatment of iron deficiency with or without anemia in adults, benefits from data exclusivity protection in Europe and the USA and has exclusive IP rights until the mid-2030s.